<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00334542</url>
  </required_header>
  <id_info>
    <org_study_id>JHOC-J0485, CDR0000477214</org_study_id>
    <secondary_id>P50CA088843</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0485</secondary_id>
    <secondary_id>SKCCC-J0485</secondary_id>
    <nct_id>NCT00334542</nct_id>
  </id_info>
  <brief_title>Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer</brief_title>
  <official_title>A Phase II Study of Simvastatin in Women at High Risk for a New Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing,
      or coming back. The use of simvastatin may keep cancer from coming back in women who are at
      high risk for a new breast cancer after undergoing surgery for ductal carcinoma in situ or
      stage I, stage II, or stage III breast cancer.

      PURPOSE: This phase II trial is studying how well simvastatin works in preventing a new
      breast cancer in women at high risk for a new breast cancer after undergoing surgery for
      ductal carcinoma in situ or stage I, stage II, or stage III breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Describe changes from baseline in a panel of biomarkers (high-sensitivity C-reactive
           protein [hsCRP], lipid profile, circulating estrogens, and contralateral breast density)
           in women at high risk of developing new breast cancer who have undergone surgical
           resection for history of ductal carcinoma in situ or stage I-III invasive breast cancer
           treated with simvastatin.

      Secondary

        -  Correlate changes in the panel of biomarkers with wild-type versus polymorphic
           3-hydroxyl-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase in women treated with
           simvastatin.

      Tertiary

        -  Evaluate methylation status across a panel of genes that are known to be frequently and
           specifically hypermethylated in ductal carcinoma in situ (DCIS) and invasive breast
           cancer (estrogen receptor [ER]-α and ER-β, cyclin D2, RAR-β, Twist, RASSF1A, and HIN-1)
           and correlate change in cumulative methylation with change in hsCRP, lipid profile,
           contralateral breast density, estrogen concentrations, and pharmacogenetics.

        -  Measure changes in the phosphoinositide 3'-kinase (PI3K)/protein kinase B (Akt)
           signaling pathway (Akt and p-Akt) before and after treatment with simvastatin.

      OUTLINE: This is a multicenter study. Patients are stratified according to menopausal status
      (pre- vs post-menopausal).

      Patients receive oral simvastatin once daily for 24-28 weeks in the absence of disease
      progression or unacceptable toxicity.

      Patients undergo blood collection at baseline and at the end of study treatment for
      pharmacogenetic and biomarker correlative studies. Patients undergo mammography and
      measurement of breast density of the contralateral breast at baseline and at the end of study
      treatment.

      Quality of life is assessed at baseline and at the end of study treatment.

      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in a Panel of Biomarkers (High-sensitivity C-reactive Protein [hsCRP], Lipid Profile, and Circulating Estrogens) From Baseline</measure>
    <time_frame>Baseline and week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in a Panel of Biomarkers (Contralateral Breast Density) From Baseline</measure>
    <time_frame>Baseline and week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Breast Gene (Estrogen Receptor [ER]-α and ER-β, Cyclin D2, RAR-β, Twist, RASSF1A, and HIN-1) Hypermethylation</measure>
    <time_frame>Baseline and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Akt and p-Akt Activation by Contralateral Core Breast Biopsies</measure>
    <time_frame>Baseline and week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 40 mg for 24-28 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>24-28 weeks of simvastatin</description>
    <arm_group_label>Simvastatin</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  History of histologically confirmed breast cancer, meeting 1 of the following staging
             criteria:

               -  Ductal carcinoma in situ

               -  Stage I-III invasive breast cancer

          -  At least 3 months since completion of all intended local and systemic therapy,
             including mastectomy or lumpectomy with or without radiotherapy, adjuvant
             chemotherapy, and/or endocrine therapy

               -  May have declined recommended treatment provided all treatment intended/agreed
                  upon by the patient and treating physician was completed ≥ 3 months ago

          -  At least 1 healthy intact breast

               -  No prior radiotherapy or mastectomy

               -  Prior biopsies allowed

          -  Any hormone-receptor status

        PATIENT CHARACTERISTICS:

          -  Female

          -  Pre- or post-menopausal

          -  ECOG performance status 0-2

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective nonhormonal contraception

          -  No active liver disease

          -  AST and ALT ≤ 3 times upper limit of normal

          -  Creatinine clearance ≥ 30 mL/min

          -  No prior hypersensitivity to any 3-hydroxyl-3-methylglutaryl-Coenzyme A (HMG-CoA)
             reductase inhibitor or any of its components

          -  No other concurrent infectious, inflammatory, or autoimmune diseases (at the
             discretion of principal investigator)

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No daily alcohol use &gt; 3 standard drinks per day

               -  Standard drink defined as 10 grams of alcohol, which is equivalent to 285 mL of
                  beer, 530 mL of light beer, 100 mL of wine, or 30 mL of liquor

          -  No selective estrogen receptor modulator or aromatase inhibitor within the past 3
             months

          -  No hormone replacement therapy (HRT) within the past 3 months

          -  No prior estrogen and/or progesterone HRT ≥ 5 years in duration

               -  Vaginal estrogen preparations allowed

          -  No concurrent HRT

          -  No other cholesterol-lowering drug, including a statin, within the past 3 months

          -  No concurrent itraconazole, ketoconazole, nefazodone, cyclosporine, HIV protease
             inhibitors, clarithromycin, erythromycin, mibefradil, carbamazepine, bosentan,
             chaparral, amiodarone, or verapamil

          -  No concurrent daily grapefruit juice consumption &gt; 8 ounces per day

          -  No other concurrent agents or therapies intended to treat or prevent in situ or
             invasive breast cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vered Stearns, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115-6084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, Jeter SC, Armstrong DK, Davidson NE, Emens LA, Fetting JH, Powers PP, Wolff AC, Green H, Thibert JN, Rae JM, Folkerd E, Dowsett M, Blumenthal RS, Garber JE, Stearns V. A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat. 2012 Feb;131(3):915-24. doi: 10.1007/s10549-011-1858-7. Epub 2011 Nov 11.</citation>
    <PMID>22076478</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2006</study_first_submitted>
  <study_first_submitted_qc>June 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2006</study_first_posted>
  <results_first_submitted>March 18, 2013</results_first_submitted>
  <results_first_submitted_qc>May 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 25, 2013</results_first_posted>
  <last_update_submitted>July 3, 2013</last_update_submitted>
  <last_update_submitted_qc>July 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>ductal breast carcinoma in situ</keyword>
  <keyword>breast cancer in situ</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From January 2005 to November 2009, 50 participants were enrolled.</recruitment_details>
      <pre_assignment_details>Participants were required to have good performance status, intact contralateral breast, and be at least 3 months from planned local and systemic adjuvant treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Simvastatin</title>
          <description>Simvastatin 40 mg for 24-28 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>New cancer diagnosis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Simvastatin</title>
          <description>Simvastatin 40 mg for 24-28 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="38" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in a Panel of Biomarkers (High-sensitivity C-reactive Protein [hsCRP], Lipid Profile, and Circulating Estrogens) From Baseline</title>
        <time_frame>Baseline and week 24</time_frame>
        <population>Paired baseline and post-simvastatin treatment fasting lipid samples were available for 47 participants, including 45 women who completed the study and from two who discontinued the drug prior to the completion of the 24–28 weeks of drug, and are integrated in the intention-to-treat analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Simvastatin 40 mg for 24-28 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in a Panel of Biomarkers (High-sensitivity C-reactive Protein [hsCRP], Lipid Profile, and Circulating Estrogens) From Baseline</title>
          <population>Paired baseline and post-simvastatin treatment fasting lipid samples were available for 47 participants, including 45 women who completed the study and from two who discontinued the drug prior to the completion of the 24–28 weeks of drug, and are integrated in the intention-to-treat analyses</population>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hsCRP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" lower_limit="-1" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54" lower_limit="-58.5" upper_limit="-39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-density lipoprotein cholesterol (HDL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estrogen (estrone sulfate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-81.5" lower_limit="-225.5" upper_limit="-40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Breast Gene (Estrogen Receptor [ER]-α and ER-β, Cyclin D2, RAR-β, Twist, RASSF1A, and HIN-1) Hypermethylation</title>
        <time_frame>Baseline and week 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Akt and p-Akt Activation by Contralateral Core Breast Biopsies</title>
        <time_frame>Baseline and week 24</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in a Panel of Biomarkers (Contralateral Breast Density) From Baseline</title>
        <time_frame>Baseline and week 24</time_frame>
        <population>Paired baseline and post-simvastatin treatment mammograms for evaluation of breast density were available for 43 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Simvastatin 40 mg for 24-28 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in a Panel of Biomarkers (Contralateral Breast Density) From Baseline</title>
          <population>Paired baseline and post-simvastatin treatment mammograms for evaluation of breast density were available for 43 participants.</population>
          <units>percentage of change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" lower_limit="-2.33" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24-28 weeks of simvastatin administration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Simvastatin</title>
          <description>Simvastatin 40 mg for 24-28 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <description>Generalized muscle pain/weakness</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Generalized muscle pain/weakness</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Vered Stearns</name_or_title>
      <organization>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</organization>
      <phone>4432876489</phone>
      <email>vstearn1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

